Thermo Fisher Scientific TRAIL-R2 (DR5) Polyclonal Antibody

Applications

Tested Dilution

Publications

Western Blot (WB)

1 µg/mL

View 4 publications 4 publications

Immunohistochemistry (IHC)

-

View 1 publication 1 publication

Immunohistochemistry (Frozen) (IHC (F))

-

View 1 publication 1 publication

Immunocytochemistry (ICC/IF)

2-3 µg/mL

-

Product Specifications

Species Reactivity

Human, Mouse, Rat

Published species

Human

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

Synthetic Peptide: C V(255) P E Q E M E V Q E P A E P T G(270)

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

1 mg/mL

Purification

Antigen affinity chromatography

Storage buffer

PBS with 1mg/mL BSA

Contains

0.05% sodium azide

Storage conditions

-20° C, Avoid Freeze/Thaw Cycles

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2303474

Product Specific Information

PA1-957 detects death receptor 5 (DR5) from human and rat tissues and cells.

PA1-957 has been successfully used in Western blot procedures. By Western blot, this antibody detects an ~58 kDa protein representing DR5 from HEK293 cell lysate.

PA1-957 immunizing peptide corresponds to amino acid residues 255-270 of rat DR5. PA1-957 immunizing peptide (Cat. # PEP-048) is available for use in neutralization and control experiments.

Target Information

DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.